Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis

N-Substituted benzamide derivatives (I) are new. Also new are methyl benzoate derivative intermediates (II). N-Substituted benzamide derivatives (I) (including thioamide, amine and amidine analogs) are new. [Image] W : O, S, H 2 or NR 8; Z 1>a direct bond, =NR 10, =N-, optionally branched 1-12C alkyl or -(CR aR b) m-(CR cR d) n-(CR eR f) o-; m, n, o : 0-3; R a-R fH, F, 1-4C alkyl or =NR 10; or R a + R c and/or R d + R ea bond; or 1 or 2 of R a-R fupto 3C bridge with R 1 or R 7; R 1alkyl, 2-12C alkenyl, 3-12C alkynyl, 3-10C cycloalkyl or 3-10C cycloalkenyl (all optionally substituted by at least one of halo and alkyl), or aryl or heteroaryl (both optionally substituted by one or more of halo, alkyl, 1-alkoxy, mono- or polyhaloalkyl and mono- or polyhaloalkoxy); R 2, R 3H, OH or XR 11; X : 2-6C alkyl, 2-6C alkenyl or 2-6C alkynyl; R 11mono- or bicyclic aryl or heteroaryl (all os by one or more of halo, alkyl, alkoxy or OH); R 4-R 6H or halo; or alkoxy, alkyl or carboxyalkyl (all optionally substituted by one or more halo), or R 4 + R 5methylenedioxy; R 7H or alkyl, or forms an up to 3C bridge with R a-R f or R 1; R 8, R 10H or alkyl; alkyl moieties have 1-6C unless specified otherwise; provided that: (i) R 2/R 3 are not H/H, H/OH or OH/H and (ii) R 1 = is not triazole. An independent claim is included for new methyl benzoate derivative intermediates of formula (II) and their isomers and salts. [Image] R 2', R 3'H or XR 11', but not both H, and R 11'phenyl or pyridyl (both optionally substituted by alkyl). - ACTIVITY : Cytostatic; antipsoriatic; antirheumatic; antiarthritic; ophthalmological; antidiabetic; nephrotropic; immunosuppressive; antiinflammatory; hepatotropic; antiarteriosclerotic; neuroprotective. - MECHANISM OF ACTION : Tyrosine kinase KDR inhibitor; tyrosine kinase FLT inhibitor; vascular endothelial growth factor (VEGF) receptor phosphorylation inhibitor. N-(4-n-propylphenyl)-2-(4-pyridylethyl)-benzamide (Ia) exhibited an IC 50 value 0.2 mu M for inhibition of both tyrosine kinases KDR and FLT.